Literature DB >> 24108586

Systemic rheumatoid vasculitis in the era of modern immunosuppressive therapy.

Eleana Ntatsaki1, Janice Mooney, David G I Scott, Richard A Watts.   

Abstract

OBJECTIVES: Systemic rheumatoid vasculitis (SRV) is a rare but potentially serious systemic disease manifestation of rheumatoid arthritis (RA) characterized by the development of necrotizing vasculitis. The incidence of SRV appears to be decreasing possibly reflecting progress in RA treatment. The aims of this study were to review the clinical manifestations of SRV in a stable well-defined population during 2001-10 and to compare with our previous cohort (1988-2000) and also a cohort from 1975 to 1981.
METHODS: Using Norfolk Vasculitis Register, a prospective register of patients with systemic vasculitis since 1988, all patients with a diagnosis of SRV from 1 January 2001 until 31 December 2010 were identified. SRV was defined according to the Scott and Bacon criteria (1984). Clinical features were obtained by retrospective case note review.
RESULTS: Eighteen patients with SRV were identified (10 male), median age at diagnosis was 72 years and average disease duration 15.6 years. The average annual incidence for 2001-10 was 3.9 per million. One-year mortality was 12% and 5-year mortality 60%. The clinical manifestations were similar apart from systemic and cutaneous features which were more common in the earlier cohorts.
CONCLUSION: The incidence of SRV has declined significantly in the last 40 years; but the clinical manifestations remain similar. Systemic symptoms, and cutaneous manifestations such as infarcts and nodules, are slightly less common in the recent cohort. Despite modern immunosuppressive therapy the prognosis remains poor.

Entities:  

Keywords:  biological therapies; epidemiology; extra-articular manifestations; immunosuppressants; rheumatoid arthritis; systemic rheumatoid vasculitis; vasculitis

Mesh:

Substances:

Year:  2013        PMID: 24108586     DOI: 10.1093/rheumatology/ket326

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  16 in total

Review 1.  Rheumatoid Vasculitis: A Diminishing Yet Devastating Menace.

Authors:  Shweta Kishore; Lisa Maher; Vikas Majithia
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

2.  Small vessel multi-organ vasculitis and marantic endocarditis complicating rheumatoid arthritis.

Authors:  Adam Morris; Piyali Pal; Edmond O'Riordan; Dimitrios Poulikakos
Journal:  Eur J Rheumatol       Date:  2019-04-22

3.  Rheumatoid arthritis: Rheumatoid vasculitis--down but not out.

Authors:  Richard A Watts
Journal:  Nat Rev Rheumatol       Date:  2014-03-04       Impact factor: 20.543

Review 4.  Gastrointestinal and Hepatic Disease in Rheumatoid Arthritis.

Authors:  Ethan Craig; Laura C Cappelli
Journal:  Rheum Dis Clin North Am       Date:  2018-02       Impact factor: 2.670

5.  Neurologic Manifestations of Rheumatoid Arthritis: A Case of Cerebral Vasculitis Treated With Rituximab.

Authors:  Mohamad Ali Rida; Maysam El Najjar; Mira Merashli
Journal:  Arch Rheumatol       Date:  2018-05-07       Impact factor: 1.472

Review 6.  Connective Tissue Disorder-Associated Vasculitis.

Authors:  Aman Sharma; Aadhaar Dhooria; Ashish Aggarwal; Manish Rathi; Vinod Chandran
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

7.  Burning vasculitis.

Authors:  Priyanka Chadha; Dorian Hobday; Edmund Fitzgerald O'Connor; David D'Cruz
Journal:  BMJ Case Rep       Date:  2016-04-26

8.  Rheumatoid Vasculitis as an Initial Presentation of Rheumatoid Arthritis.

Authors:  Sravani Lokineni; Mohamed Amr; Leela Krishna Teja Boppana; Megha Garg
Journal:  Eur J Case Rep Intern Med       Date:  2021-04-29

9.  An arm and a leg: A case of rheumatoid vasculitis and antiphospholipid antibody syndrome.

Authors:  Jay Ghadiali; Aditya Talwar; Colin Ligon
Journal:  SAGE Open Med Case Rep       Date:  2021-05-20

10.  Rheumatoid vasculitis: going, going, but not yet gone.

Authors:  David S Pisetsky
Journal:  Arthritis Res Ther       Date:  2015-05-08       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.